LAS VEGAS, NV / ACCESS Newswire / September 29, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company pioneering the development of functional mushroom technologies, announced today that it has entered an agreement with Automated Technical Services to design and build a commercial-scale Mushroom Accelerator. This scaled-up system will produce Hypha's proprietary mushroom-based ingredients for sale to nutraceutical manufacturers worldwide.
The Mushroom Accelerator is Hypha's breakthrough smart appliance that compresses the production of potent, functional mushroom compounds from months to just eight days. While the current countertop unit serves home and small-scale users, the new collaboration with ATS will enable Hypha to expand into large-scale ingredient production for the booming $33 billion global functional mushroom market-projected to reach $49 billion by 2028.
Under the agreement, ATS will work closely with Hypha's R&D team to adapt the proprietary processes developed in Hypha's laboratory units to a full-scale, commercial production environment. This will allow Hypha to supply its novel mushroom-derived compounds to nutraceutical brands, supplement manufacturers, and direct-selling companies seeking new "hero" ingredients to power their formulations.
Craig Ellins, Chief Scientific Officer of Hypha Labs, stated, "This agreement is a major step in taking our Mushroom Accelerator technology from the kitchen counter to industrial production. With ATS's engineering expertise, we'll be able to bring our unique formulations to market at a scale that meets the needs of leading nutraceutical companies."
Garren Holman, CEO of ATS, added, "Scaling from lab to commercial production requires precision engineering and an understanding of the unique challenges involved. We're excited to partner with Hypha Labs on this groundbreaking project and look forward to delivering a robust, scalable solution."
Hypha Labs is currently conducting a Regulation A+ public offering, providing early investors with the opportunity to participate in the company's growth as it expands from consumer-focused devices to large-scale ingredient production.
For details on the Reg A+ campaign, visit: Invest.hyphalabs.com
About Automated Technical Services (ATS)
ATS Develops and deploys tailored integrations between enterprise applications, cloud platforms, and legacy systems, using APIs, middleware, and automation tools to make otherwise incompatible systems work together.
About Hypha Labs, Inc.
The company has developed revolutionary, cutting-edge technology focused on new methods of producing the active ingredients found in a wide array of functional mushrooms using its patent-pending mushroom accelerators. The Company is positioning itself to play an important role in the burgeoning Functional Mushroom industry in addition to being a disruptive force in future and emerging mushroom opportunities. Visit us at HyphaLabs.com.
SAFE HARBOR FORWARD LOOKING STATEMENTS:
This press release may contain forward looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
From time to time, the Company may post new and material information on its website or through its social media profiles at the links below:
LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs
For more information about Hypha Labs visit HyphaLabs.com
For the Company's current Investor Presentation please visit www.HyphaLabs.com/deck
Investor and Media Relations:
Integrity Media Inc.
(888) 216-3595
team@integritymedia.com
SOURCE: Hypha Labs, Inc.
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/hypha-labs-and-automated-technical-services-ats-enter-into-agreement-1079151
